Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010:2010:617521.
doi: 10.1155/2010/617521. Epub 2009 Nov 1.

Drug resistance in visceral leishmaniasis

Helena C Maltezou  1
Affiliations
Review

Drug resistance in visceral leishmaniasis

Helena C Maltezou. J Biomed Biotechnol. 2010.

Abstract

Visceral leishmaniasis remains a public health problem worldwide. This illness was included by the World Health Organization in the list of neglected tropical diseases targeted for elimination by 2015. The widespread emergence of resistance to pentavalent antimonials in India where half cases occur globally and the unavailability of a vaccine in clinical use constitute major obstacles in achieving of this goal. The last decade new antileishmanials became available, including the oral agent miltefosine. However, in poor endemic countries their wide use was curtailed because of the high costs, and also due to concerns of toxicity and emergence of resistance. Various mechanisms of antileishmanial resistance were identified recently in field isolates. Their elucidation will boost the design of new drugs and the molecular surveillance of resistance. Combination regimens should be evaluated in large trials. Overall, the development of antileishmanials has been generally slow; new drugs are needed. In order to control visceral leishmaniasis worldwide, treatment advances should become affordable in the poorest countries, where they are needed most.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Leishmaniasis: burden of disease. August 2009, http://www.who.int/leishmaniasis/burden/en.
    1. Maltezou HC, Siafas C, Mavrikou M, et al. Visceral leishmaniasis during childhood in Southern Greece. Clinical Infectious Diseases. 2000;31(5):1139–1143. - PubMed
    1. Minodier P, Piarroux R, Garnier J-M, Unal D, Perrimond H, Dumon H. Pediatric visceral leishmaniasis in Southern France. Pediatric Infectious Disease Journal. 1998;17(8):701–704. - PubMed
    1. Raguenaud M-E, Jansson A, Vanlerberghe V, et al. Epidemiology and clinical features of patients with visceral leishmaniasis treated by an MSF clinic in Bakool Region, Somalia, 2004–2006. PLoS Neglected Tropical Diseases. 2007;1(1, article e85) - PMC - PubMed
    1. World Health Organization. Global plan to combat neglected tropical diseases 2008–2015. August 2009, http://whqlibdoc.who.int/hq/2007/WHO_CDS_NTD_2007.3_eng.pdf.

MeSH terms

Substances

LinkOut - more resources